Financial Performance - The company reported a revenue increase of 10% year-over-year, reaching $1.2 billion in Q3 2023[5]. - The company reported a revenue of $1.2 billion for the last quarter, representing a 15% increase year-over-year[1]. - The company provided a forward guidance of 12% revenue growth for the next quarter, projecting revenues between $1.35 billion and $1.4 billion[5]. - The company expects revenue growth of 10-12% for the next fiscal year, driven by new product launches and market expansion[3]. - The gross margin improved to 45%, up from 42% in the previous quarter, due to cost optimization strategies[7]. - The company has set a target to reduce operational costs by 15% over the next year through efficiency improvements[8]. - The company is committed to ESG initiatives, allocating $50 million towards environmental and social governance projects[5]. - Liquidity remains strong with cash reserves of $500 million, ensuring financial stability for future investments[5]. Market and User Growth - User data showed a growth of 15% in active users, totaling 5 million by the end of the quarter[5]. - User data showed a growth of 25% in active users, reaching 5 million by the end of the quarter[2]. - New product launches contributed to a 20% increase in sales, with the latest product line accounting for $250 million in revenue[5]. - Market expansion efforts have led to a 25% increase in market share in the Asia-Pacific region[5]. - The company plans to expand its market presence in Asia, targeting a 30% increase in market share within the next two years[5]. Strategic Initiatives - The company completed a strategic acquisition of a competitor for $300 million, expected to enhance its product offerings[5]. - A strategic acquisition was completed, adding $300 million in annual revenue and enhancing the company's product portfolio[6]. - The company is investing $100 million in R&D for new technologies aimed at enhancing user experience[5]. - The company is exploring partnerships to enhance its distribution network, aiming for a 25% increase in delivery efficiency[10]. Operational Risks and Challenges - The company is exposed to operational risks including supply chain interruptions and natural disasters, which could significantly impact production levels and financial results[31]. - The company’s financial performance is highly dependent on international market prices of metals, which are cyclical and volatile, potentially affecting revenues and cash flow[35]. - The company faces risks related to regulatory changes, including new trade restrictions and tariff escalations, which could adversely affect operations and financial performance[31]. - The company’s operations are subject to various compliance risks, including potential litigation and administrative proceedings that could materially impact financial performance[38]. - The company is exposed to operational risks that may result in increased costs or delays in project implementation, affecting growth prospects and profitability[86]. - The company is vulnerable to cyber events and IT system failures, which could disrupt business continuity and operational efficiency[31]. Compliance and Regulatory Environment - The company is classified as a non-accelerated filer under the SEC regulations[3]. - Nexa Resources S.A. has confirmed compliance with all reporting requirements under the Securities Exchange Act of 1934 for the past 12 months[3]. - The company is required to comply with the EU Corporate Sustainability Reporting Directive, which will apply to it starting in 2027 due to its employee and revenue thresholds[153]. - The company is subject to anti-corruption and anti-bribery laws across various jurisdictions, with potential violations leading to material adverse effects on its reputation and financial position[151]. Environmental and Social Governance (ESG) - The company is committed to meeting ESG standards, with failure to do so potentially affecting its reputation and financial condition[35]. - The company faces significant risks and uncertainties in achieving its ESG goals, including potential increases in operational costs related to monitoring and reporting[67]. - The company may incur additional expenses due to failures in its environmental control equipment, which could adversely affect its reputation and operations[147]. Production and Mining Operations - The company operates five polymetallic mines and three zinc smelters, with zinc as the main product, highlighting its extensive operational footprint in Latin America[18]. - In 2025, the company produced 315.6 thousand tonnes of zinc contained in concentrates, a decrease of 3.5% compared to 2024, primarily due to mining in lower-grade areas at the Vazante mine[171]. - Total smelting production in 2025 decreased by 5.1% compared to 2024, with smelters producing 564.4 thousand tonnes of zinc metal and oxide available for sale[174]. - The company was ranked among the top six global zinc producers in 2025, with zinc accounting for 46.9% of mined metal production on a zinc equivalent basis[171]. - The company has interests in three greenfield projects in Peru and owns 12.15% of Tinka Resources Limited, which holds the Ayawilca zinc-silver development project[189]. Financial Position and Debt - As of December 31, 2025, Nexa Resources S.A. had 132,438,611 common shares outstanding, each with a par value of US$1.00[3]. - The company’s ability to pay dividends is subject to various factors, including cash flow and earnings, with no current contractual restrictions on dividend payments[83]. - As of December 31, 2025, 21.2% of the company's total debt was subject to variable/floating interest rates, exposing it to interest rate fluctuations[132]. - The company’s access to capital markets may be limited by potential downgrades in its credit ratings, which could increase borrowing costs and trigger default clauses[136]. Tax and Legal Matters - The company faces a tax assessment totaling approximately $17.5 million from the Peruvian tax authority due to challenges regarding the deductibility of losses from hedge transactions[134]. - The company is engaged in ongoing tax-related matters with the Peruvian tax authority, which may impact its results, cash flow, and liquidity[164]. - The company has reclassified its derivative instruments as speculative for tax purposes since fiscal year 2019 to mitigate future deductibility challenges[134]. Community and Political Factors - Recent political instability in Peru, including the impeachment of President José Jeri, has increased uncertainty regarding economic policies, potentially impacting investor confidence[72]. - Protests and disputes with local communities have led to production losses, with an estimated zinc production loss of approximately 1.2kt due to a seven-day suspension at the Atacocha and El Porvenir mines[75]. - The establishment of the REINFO program in Peru has increased informal mining activities, potentially adversely affecting the company's operations and projects[157].

Revenue and Profitability - Revenue for 2025 was $11,890,000, representing a 1.8% increase from $11,679,000 in 2024[165] - Gross profit decreased to $4,630,000 in 2025, with a gross margin of 38.9%, down from $4,846,000 and 41.5% in 2024[168] - The company reported a net loss of $1,615,000 in 2025, compared to a net loss of $1,984,000 in 2024[165] - Revenue from the industrial market increased by 52.3% to $4,009,000 in 2025, while revenue from the medical market decreased by 7.6% to $3,629,000[166][167] Expenses - Engineering, research and development expenses were $1,504,000 in 2025, a decrease of 26.7% from $2,052,000 in 2024[169] - Selling, general and administrative expenses increased to $4,955,000 in 2025, up 2.3% from $4,844,000 in 2024[170] Cash Flow and Working Capital - Cash and cash equivalents as of December 31, 2025, were $2.7 million, with working capital of $4.6 million and no indebtedness[176] - For the year ended December 31, 2025, net cash used in operating activities was $112,000, attributed to a net loss of $1,615,000, adjusted for non-cash charges of $519,000 and cash provided by changes in operating assets and liabilities of $984,000[179] - Net cash used in investing activities for 2025 was $56,000, compared to $491,000 in 2024, which included $314,000 for acquiring assets of Conductive Transfers[181] - Net cash used in financing activities for 2025 was $91,000, consisting of $242,000 from the issuance of Common Stock, offset by $333,000 in dividends on Preferred Stock[182] Strategic Initiatives - The company expanded its capabilities through acquisitions, including Calman in 2023 and Conductive Transfers Limited in 2024, enhancing its product offerings and market presence[160] - The company prioritizes revenue growth in strategic markets and aims for gross margin expansion through favorable product mix and operational efficiencies[162] Tax and Financial Reporting - The effective tax rate is expected to remain higher than the U.S. statutory rate of 21% due to earnings in higher-rate jurisdictions[174] - The company recognizes revenue when goods or services are transferred to customers, following a five-step process as per ASC Topic 606[187] - The company evaluates the collectability of accounts receivable at each balance sheet date, using historical experience and economic conditions[190] - Goodwill is tested for impairment at least annually, with assessments requiring management judgment on qualitative and quantitative factors[191] Balance Sheet Items - Accounts receivable decreased from $1,612,000 at December 31, 2024 to $1,542,000 at December 31, 2025, reflecting changes in shipment timing and cash collections[180] - Inventories decreased from $2,009,000 at December 31, 2024 to $1,801,000 at December 31, 2025, primarily due to variability in material purchases and customer demand[180] - The company did not have any off-balance sheet arrangements as of December 31, 2025 and 2024, indicating no exposure to related financial risks[184] Financial Instruments - The conversion of Series A Convertible Preferred Stock into Common Stock resulted in annual cash savings of $400,000 by eliminating an 8.0% cumulative cash dividend[177]

Store Operations and Expansion - Ulta U.S. operates over 1,500 retail stores, with plans to grow to more than 1,800 stores, targeting a market valued at approximately $126 billion in 2025[26][30]. - As of January 31, 2026, the company operated a total of 1,591 retail stores, with 1,505 located in the United States and 86 internationally[183]. - The company operates 84 Space NK stores in the U.K. and two in Ireland, with additional locations in Mexico, Kuwait, and the UAE[52]. - The company expanded internationally in 2025 through the acquisition of Space NK and established a joint venture in Mexico, indicating a strategic move towards market expansion[128]. - The company’s retail stores are predominantly located in high-traffic areas, with typical store sizes around 10,000 square feet[181]. Loyalty Program and Customer Engagement - In fiscal 2025, 73% of Ulta U.S.'s loyalty members transacted solely in physical stores, highlighting the preference for in-store shopping[28]. - The loyalty program has over 46 million members, contributing approximately 95% of total sales in fiscal 2025, with loyalty members historically spending over three times as much as store-only guests[42][32]. - Digital channels accounted for 19% of loyalty members shopping both in-store and online, emphasizing the importance of omnichannel engagement[32]. - The company’s loyalty program provides insights into customer preferences, enhancing its ability to deliver personalized experiences[206]. Product Offerings and Marketplace - Ulta U.S. offers approximately 30,000 products from around 600 brands, with top ten brand partners accounting for approximately 51% of total net sales in fiscal 2025[36][37]. - The launch of UB MarketplaceTM in fiscal 2025 allows Ulta U.S. to expand its product assortment with minimal inventory risk, earning commissions on sales from marketplace brands[47][49]. - The Company’s private label and exclusive products represented approximately 4% of net sales in fiscal 2025, with exclusive products contributing to 11% of total net sales[38]. Digital and Technological Advancements - Ulta U.S. is enhancing its digital capabilities, including faster online order fulfillment and features like virtual try-on, to improve customer experience[35][34]. - The Company has made significant investments in technology infrastructure, including upgrading its enterprise resource planning platform and POS systems[72]. - The company is expanding and upgrading its information systems to support growth, which is critical for managing operations and e-commerce[141]. - The development and effective use of AI technologies are critical, as failure to adapt could negatively impact competitive positioning and financial results[112]. Financial Performance and Market Conditions - The company’s business is subject to seasonal fluctuations, with significant net sales and profits realized during the fourth quarter due to the holiday selling season[86]. - Macroeconomic conditions, including inflation and elevated interest rates, have negatively impacted the company's financial condition and profitability, with expectations of continued pressure into 2026[90]. - Consumer purchases of discretionary items, including beauty products, may decline due to economic uncertainty, adversely affecting the company's financial performance[92]. - Operating profit is anticipated to increase due to revenue growth, leveraging fixed costs, and improving operating efficiencies, despite incremental investments in guest experience and advertising[210]. Risks and Challenges - The company faces risks from geopolitical events, which could have a greater impact on its international operations compared to when it was solely U.S.-based[91]. - The company must manage inventory effectively to avoid excess stock or shortages, as miscalculations could harm financial performance[105]. - The company is increasingly vulnerable to cybersecurity risks, which could compromise sensitive information and negatively impact business operations[143]. - The company is subject to various regulatory requirements affecting its product offerings, including labeling and safety standards[81]. Marketing and Brand Strategy - The company is directing a growing percentage of its marketing expenses towards digital and social media to enhance brand awareness and attract new customers[43]. - The company believes its trademarks, especially those related to the Ulta Beauty brand, have significant value for brand recognition[79]. - The company aims to drive core business growth through operational excellence and an elevated go-to-market approach, focusing on three strategic priorities: core business growth, scaling new businesses, and aligning for future success[207]. Supply Chain and Distribution - The Company operates four regional distribution centers and two market fulfillment centers to support both stores and e-commerce demand[70]. - The company operates four regional distribution centers and one fast fulfillment center, with plans for future growth and optimization of its distribution infrastructure to support anticipated growth[123]. - Increased costs or interruptions in third-party vendors' overseas sourcing operations could disrupt production and shipment, potentially leading to lost sales and increased costs[124]. Corporate Governance and Compliance - The company has established science-based targets to reduce Scope 1, 2, and 3 greenhouse gas emissions as part of its sustainability strategy[75]. - The company is subject to litigation and regulatory proceedings that could materially adversely affect its business and financial condition, with potential losses exceeding accrued liabilities[152]. - The company maintains a stock repurchase program that may affect stock price but does not guarantee enhanced shareholder value[139].

Product Development - Vivani Medical is developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal™ technology, aimed at improving medication adherence for chronic diseases [453]. - Vivani's lead program, NPM-139, a six-month GLP-1 (semaglutide) implant, demonstrated approximately 20% weight loss in preclinical studies, maintained for over six months after a single administration [456]. - The NPM-115 exenatide implant showed comparable weight loss results of approximately 20% in preclinical studies with obese mice, indicating potential for effective chronic weight management [459]. - The FDA lifted the clinical hold on NPM-119, allowing for the initiation of a first-in-human study for the treatment of type 2 diabetes [465]. - Vivani plans to initiate a Phase 1 clinical study for NPM-139 in the first half of 2026, pending regulatory clearance [472]. - The LIBERATE-1 clinical trial for NPM-115 demonstrated a positive safety and tolerability profile, with top-line data released in August 2025 [463]. Financial Performance - The company has experienced recurring operating losses and negative cash flows since inception, with expectations to continue this trend for the foreseeable future [492]. - Net loss for the year ended December 31, 2025 was $26.6 million, an increase of $3.1 million compared to a net loss of $23.5 million in 2024 [512]. - Cash used in operating activities during 2025 was $24.3 million, compared to $20.8 million in 2024 [514][515]. - Net cash used in investing activities was $1.2 million in 2025, up from $0.6 million in 2024 [516]. - Financing activities provided $23.3 million of cash in 2025, primarily from a registered direct offering and securities purchase agreements [516]. Capital and Funding - On March 1, 2024, the company raised $15 million through a registered direct offering of 3,947,368 shares at $3.80 per share, resulting in net proceeds of $13.7 million after issuance costs [478]. - On April 22, 2024, the company entered into an Open Market Sale Agreement to offer up to $75 million in common stock through Jefferies LLC [479]. - In 2025, the company issued 7,480,158 shares under private sales transactions, generating gross proceeds of $8.6 million, with an expected additional $12.6 million from remaining shares in 2026 [486]. - On October 26, 2025, the company completed a private placement of 3,703,703 shares at $1.62 per share, resulting in gross proceeds of $6 million [487]. - Concurrently, the company raised approximately $9.7 million from a registered direct offering of 6,000,000 shares, netting $8.7 million after fees [489]. - The company received $35,000 in grants during the twelve months ended December 31, 2025, compared to $200,000 in the previous year, reflecting a decrease in grant funding [491]. Research and Development - Research and development expense for the year ended December 31, 2025 was $18.1 million, an increase of $2.4 million or 15% compared to $15.7 million in 2024 [509]. - The company expects research and development expenses to increase in the future as it pursues enhancements of existing products and develops new technologies [513]. Strategic Initiatives - Vivani is exploring strategic options for its neurostimulation technology through its subsidiary Cortigent, including a potential spin-off or IPO [474]. - If Cortigent successfully completes an IPO, it will repay Vivani $1.5 million from the proceeds and issue a promissory note for $2 million [475]. - The strategic goal of the potential spin-off or IPO is to create two focused companies to enhance value in their respective therapeutic areas [476]. - On April 12, 2025, Okava Pharmaceuticals expanded its collaboration with Vivani to include the development of a long-acting GLP-1 therapy for dogs, adding $5 million in regulatory milestone payments for obesity treatment [477]. Operational Outlook - The company estimates that available cash will meet its obligations into mid-2027, but additional capital will be necessary for ongoing operations [493]. - The company is subject to risks associated with developing pharmaceutical products, including significant increases in operating expenses as clinical trials and research activities expand [496]. - General and administrative expense for the year ended December 31, 2025 was $9.4 million, up $0.5 million or 6% from $8.9 million in 2024 [510]. - The company has not declared or paid dividends and has no plans to do so in the foreseeable future [507]. - As of December 31, 2025, the company had no off-balance sheet arrangements [518]. - The majority of operating expenses were denominated in U.S. dollars, with no foreign currency forward contracts currently in place [520].

Financial Performance - The company has incurred significant net losses since its inception and anticipates continuing to incur net losses for the foreseeable future [134]. - The company incurred net losses of $48,259,189 and $27,519,886 for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $142,679,800 as of December 31, 2025 [153]. - The company anticipates that net losses will increase in the foreseeable future due to rising business costs associated with advancing its clinical development program and seeking regulatory approval for IKT-001 [154]. - Cash, cash equivalents, and marketable securities totaled $178,764,028 as of December 31, 2025, but the company may exhaust its available capital resources sooner than expected [156]. Revenue Generation - As of the date of the report, the company has not generated any revenue from product sales and does not expect to do so in the near future [135]. - The successful development and commercialization of product candidates will require substantial additional funding beyond current financial resources [159]. Funding and Capital - In October 2024, the company completed a private placement of approximately $110 million [138]. - The company completed an underwritten public offering of approximately $115 million in November 2025 [138]. - The company has no committed source of additional capital, which may hinder its ability to continue operations or capitalize on business opportunities [159]. - Market volatility and potential future epidemics could adversely impact the company's ability to access capital when needed [159]. Product Development and Regulatory Approval - The company is highly dependent on the success of its initial product candidate, IKT-001, targeting pulmonary arterial hypertension (PAH) [134]. - The regulatory approval processes for the company's product candidates are lengthy, costly, and inherently unpredictable [134]. - The company plans to seek regulatory approval for its product candidates in the United States, EU, and other countries, but has never submitted an application for approval [174]. - The company has not completed any registrational clinical trials and faces significant challenges in successfully developing and commercializing IKT-001 [167]. - The company may face significant delays in its current and planned clinical trials, which could inhibit regulatory approval or market acceptance [134]. Clinical Trials - Clinical trials are expensive and time-consuming, with potential delays that could impair the ability to generate revenue [178]. - The success of clinical trials is uncertain, and failure can occur at any stage, impacting the ability to receive regulatory approval [189]. - The company may face challenges in patient enrollment for clinical trials, which could adversely affect trial completion and timelines [182]. - The company may encounter significant adverse events or side effects in clinical trials that could inhibit regulatory approval or market acceptance of its product candidates [168]. Competition - The company operates in a highly competitive environment, with significant competition from major pharmaceutical companies and research organizations [195]. - Competitors in the cardiopulmonary disease area include GlaxoSmithKline, Johnson and Johnson, and Merck and Co., among others [196]. - The company faces significant competition from larger firms with greater financial resources and expertise in research, development, and marketing, which could limit its commercial opportunities [197]. Manufacturing and Supply Chain - The company has limited manufacturing experience and relies on third-party suppliers for key raw materials [139]. - Manufacturing of product candidates is complex and reliant on external expertise, with potential delays in production affecting clinical trials and commercialization [199]. - The company completely outsources its manufacturing and does not have any manufacturing facilities, relying on third-party manufacturers for materials [289]. - The company relies on a small number of third-party suppliers for key raw materials, which poses risks related to pricing, availability, and quality [296]. Intellectual Property - The company has filed patent applications for its product candidates, but there is no assurance that these will be granted [301]. - The patent prosecution process is complex and costly, which may hinder the ability to protect intellectual property effectively [304]. - Loss of patent protection could adversely affect the company's competitive position and ability to commercialize products [305]. - The company may face challenges in protecting its intellectual property rights globally, as enforcement in foreign jurisdictions can be prohibitively expensive and less effective than in the United States [312]. Regulatory Risks - Regulatory approval processes for manufacturing are stringent, and failure to meet these standards could delay product commercialization [203]. - Changes in regulatory requirements or clinical trial design could materially affect the ability to conduct trials as planned [192]. - Non-compliance with regulatory requirements could lead to significant penalties, adversely affecting the company's value and operating results [249]. Compliance and Legal Risks - Compliance with healthcare laws is critical, as violations could lead to substantial penalties and negatively impact business operations [264][269]. - The company is subject to various privacy laws, including the California Consumer Privacy Act (CCPA), which may increase compliance costs and potential liabilities [272]. - The EU General Data Protection Regulation (GDPR) imposes extensive obligations on the company, with penalties for breaches reaching up to €20 million or 4% of global annual turnover, whichever is higher [275].

Revenue and Financial Performance - Total revenues for Sanuwave in 2025 reached $44.1 million, a 35% increase from $32.6 million in 2024[23]. - Revenue for the year ended December 31, 2025 was $44.1 million, a 35% increase from $32.6 million in 2024, driven by a 24% increase in UltraMIST® consumables sold and a 67% increase in UltraMIST® systems sold[206]. - Gross margins improved to 77% in 2025, up from 75% in 2024[198]. - Operating income rose by 29% to $4.9 million for the year ended December 31, 2025, compared to $3.8 million in 2024[198]. - Net income for 2025 was $11.8 million, or $1.38 per basic share, a significant increase from a net loss of $33.1 million in 2024[199]. - The increase in net income of $44.9 million was largely driven by a non-cash change in the fair value of derivatives and improved operational performance[199]. - Cash flows from operating activities for 2025 totaled $3.9 million, primarily from net income of $11.8 million adjusted for non-cash items[219]. - The company had an accumulated deficit of $242.7 million as of December 31, 2025, but successfully refinanced its debt, improving its financial position[213][215]. - Management believes the company has sufficient resources to meet its obligations for at least the next 12 months following successful refinancing and operational improvements[216]. Product and Market Overview - UltraMIST systems and consumables accounted for approximately 99% of total revenues in 2025, up from 98% in 2024[23]. - UltraMIST consumables generated about 58% of total revenues in 2025, expected to remain the largest revenue stream[35]. - As of December 31, 2025, there were 1,292 active UltraMIST systems in the field[35]. - The U.S. wound care market is estimated to exceed $67 billion annually, with growth driven by an aging population and rising incidences of chronic conditions[37][39]. - The UltraMIST system is FDA cleared and has category one reimbursement under CMS code 97610, facilitating its adoption by healthcare providers[27]. - The company holds over 60 patents related to its technology, providing a competitive advantage in the wound care market[55]. Strategic Initiatives - The Company aims to build a direct sales force and distribution network to enhance UltraMIST adoption in the U.S. and explore international expansion[40]. - Sanuwave's strategy focuses on transitioning wound care to a consultative model, improving patient outcomes while reducing treatment costs[46]. - The company may seek to expand operations and product lines through acquisitions, potentially increasing capital requirements[111]. Compliance and Regulatory Environment - The company must comply with FDA's current Good Manufacturing Practices (cGMP), which include quality control and assurance, and failure to comply may result in legal or regulatory actions[77]. - The company is registered as a Small Business Manufacturer with the FDA, which currently allows for reduced fees; however, if revenues exceed a certain threshold, full fees will apply[70]. - The company anticipates increased operational costs due to compliance with HIPAA and state-specific privacy laws as it expands its business[153]. - Noncompliance with HIPAA and related regulations could have a material adverse effect on the company's business and financial condition[154]. - The medical device industry is heavily regulated by the FDA, and failure to comply with regulations could lead to enforcement sanctions and product recalls[158]. Operational Challenges - The company faces competition from established medical device and pharmaceutical companies, which have greater financial resources and expertise[112]. - The company may face challenges in maintaining sufficient liquidity and positive operating results in the future[108]. - The company has identified material weaknesses in internal control over financial reporting, which had not been remediated as of December 31, 2025[100]. - Rapid growth may strain the company's resources, including personnel and IT systems, potentially affecting development and commercialization goals[127]. - Manufacturing output must increase to meet customer demand, with potential difficulties in manufacturing yields and component supply impacting revenue generation[128]. Cybersecurity and Data Protection - The company relies heavily on sophisticated information technology systems, facing risks from cybersecurity breaches and data leakage, which could negatively impact operations[124]. - Previous cybersecurity breaches from email spoofing have occurred, and despite investments in data protection, there is no assurance that future breaches can be prevented[125]. - The company has not experienced a material information security breach incident, but future incidents could have a material impact on its business strategy and financial condition[188]. Financial Reporting and Tax Liabilities - The company identified a historical state and local sales tax liability of approximately $44.2 million related to prior periods, necessitating a restatement of prior financial statements[101]. - The company has never paid cash dividends and does not anticipate doing so in the foreseeable future[180]. - General and administrative expenses rose to $19.4 million in 2025, a 50% increase from $12.9 million in 2024, primarily due to increased headcount and stock-based compensation[209]. - Selling and marketing expenses increased by 17% to $7.4 million in 2025, driven by higher headcount expenses and stock-based compensation[210]. - Research and development expenses doubled to $1.4 million in 2025 from $0.7 million in 2024, reflecting increased project and consulting costs[211]. Intellectual Property and Competitive Position - The protection of intellectual property is critical, and failure to secure patents could adversely affect the company's competitive position[160]. - The degree of intellectual property protection is uncertain, and challenges to patents could limit the company's ability to stop competitors[162]. - The company relies on trade secrets and proprietary know-how, and breaches of confidentiality agreements could harm its competitive position[163]. - Patent applications may not result in issued patents, and competitors may commercialize similar discoveries[165]. - Enforcing patents against third parties may require significant expenditures, impacting the company's competitiveness[169].

Cash Flows - Net cash flows from operating activities in 2025 amounted to US$ 4,959 million, a decrease of US$ 910 million from US$ 5,869 million in 2024[674]. - Net cash flows used in investing activities in 2025 were US$ 5,527 million, an increase of US$ 16 million compared to US$ 5,511 million in 2024, primarily due to acquisitions from business combinations[677]. - Net cash flows from financing activities in 2025 were US$ 517 million, primarily due to proceeds from loans net of debt repayments of US$ 1,610 million[678]. Debt and Liabilities - Total debt as of December 31, 2025, was US$ 14,082 million, with US$ 2,870 million maturing in less than one year[684]. - As of December 31, 2025, total other liabilities amounted to US$ 6,404 million, including provisions for lawsuits and environmental liabilities[684]. - The company committed to purchase goods and services for approximately US$ 6,735 million as of December 31, 2025, with US$ 1,778 million maturing in less than one year[679]. Capital Expenditures and Commitments - Capital expenditures in 2025 totaled US$ 4,993 million, with 75.7% allocated to upstream activities[683]. - Exploration and development commitments until the expiration of main permits amounted to US$ 699 million as of December 31, 2025[681]. Asset Management and Impairment - The recoverable amount of property, plant and equipment, intangible assets, and right-of-use assets is analyzed at year-end or when impairment indications arise[703]. - A hypothetical reduction of crude oil prices by US$ 5/bbl and natural gas prices by US$ 0.5/MBtu could decrease future cash flows for impairment by approximately US$ 3.1 billion, although no impairment loss would need to be recorded[703]. - Significant estimates and key sources of estimation uncertainty are detailed in the financial statements, impacting the assessment of asset impairment[702]. Operational Impact - The Argentine government's actions significantly impact the oil and gas industry, affecting company operations and financial performance[701]. Strategic Initiatives - The optimization plan of the conventional upstream portfolio includes the disposal of non-core assets, with significant progress made in 2025[686]. - The company executed an assignment agreement for the transfer of 100% of rights and obligations in certain exploitation concessions in January 2026[688].

Financial Performance - Research and development expenses decreased by approximately $0.3 million in 2025 to $6.283 million compared to $6.630 million in 2024, primarily due to increased government grants and a decrease in professional services [247]. - Sales, general and administrative expenses increased by approximately $3.5 million in 2025 to $8.460 million compared to $4.995 million in 2024, driven by higher payroll and related expenses for sales and marketing, as well as increased professional services [248]. - Financing income increased significantly by approximately $1.1 million in 2025 to $1.285 million compared to $182,000 in 2024, attributed to higher market gains on marketable securities [249]. - As of December 31, 2025, Microbot had a net working capital of approximately $76.4 million, a significant increase from $3.4 million as of December 31, 2024 [250]. - Since inception through December 31, 2025, Microbot has raised approximately $168.3 million in cash proceeds, with a total cumulative loss of approximately $104.1 million [251]. - As of December 31, 2025, Microbot has not recognized any revenues and anticipates continued net losses as it ramps up manufacturing and commercialization efforts [250]. Grants and Funding - Microbot received grants totaling approximately $2.5 million from the Israeli Innovation Authority for research and development activities, including a recent grant of approximately $673,000 approved in July 2025 [252]. - The company plans to continue raising capital through public and private issuances to fund commercialization activities for the LIBERTY Endovascular Robotic Surgical System, expected to launch in April 2026 [255]. - Microbot is obligated to pay royalties of 3%-5% on future sales related to grants received, with no repayment required if the project fails [253]. Cash Flow and Investments - Net cash flows used in operating activities increased to $(13,046) thousand in 2025 from $(8,827) thousand in 2024 [258]. - Net cash flows used in investing activities decreased to $(72,384) thousand in 2025, primarily due to increased purchases of marketable securities compared to 2024 [259]. - Net cash flows provided by financing activities rose to $86,240 thousand in 2025, attributed to increased issuances of common stock and warrants [259]. - The net increase in cash, cash equivalents, and restricted cash was $810 thousand in 2025, up from $646 thousand in 2024 [258]. Market and Operational Risks - Microbot's primary exposure to market risk is interest income sensitivity, which is affected by changes in U.S. interest rates [260]. - A significant portion of Microbot's business and operating expenses are conducted in currencies other than the U.S. dollar, exposing the company to foreign exchange risks [261]. - Exchange rate fluctuations may adversely impact future profitability and expenses, with potential credit loss from non-performance by counterparties of foreign currency contracts [262]. - Inflation has generally increased research and development expenses, but Microbot does not believe it significantly impacted results of operations for the periods presented [263]. Product Development - The LIBERTY Endovascular Robotic Surgical System is designed to eliminate the need for extensive capital equipment and dedicated staff, targeting the peripheral vasculature market [233].

Market Opportunities and Growth Strategies - The RFID and IoT solutions have been integrated into over 1.5 billion applications globally, showcasing significant market penetration[16]. - The company aims to grow its market share and profitability by focusing on higher margin opportunities and optimizing its manufacturing facility in Thailand[24]. - The healthcare growth initiative targets medication adherence, consumable authentication, and condition monitoring, addressing significant unmet needs in the market[26]. - A multi-year exclusive supply agreement was signed with IFCO to develop next-generation smart BLE labels for reusable plastic containers, indicating strategic market expansion[27]. - The company’s growth strategy includes three pillars: Perform, Accelerate, and Transform, aimed at optimizing core business, accelerating growth initiatives, and pursuing inorganic growth opportunities[23]. - The RFID market opportunity is projected to reach hundreds of billions of units over time, driven by digitization and IoT expansion[22]. Financial Performance and Results - Net revenue for 2025 was $21.5 million, a decrease of 19% from $26.6 million in 2024, primarily due to lower unit sales of RFID transponder products and reduced sales to the largest customer[141]. - Gross profit increased to $1.3 million in 2025 from $0.3 million in 2024, resulting in a gross profit margin of 6.1%, up from 1.3% in the previous year[142][143]. - The net loss from continuing operations for 2025 was $18.003 million, compared to a loss of $25.911 million in 2024, showing an improvement in operational performance[206]. - Total operating expenses for 2025 were $23.453 million, down from $28.301 million in 2024, reflecting a reduction in costs[206]. - The company reported interest income of $5.023 million in 2025, significantly higher than $1.352 million in 2024, contributing positively to the financial results[206]. Operational Challenges and Risks - The company experienced delays and reductions in customer orders during fiscal years 2025 and 2024 due to adverse macroeconomic conditions[59]. - The global semiconductor shortage that began in 2021 negatively impacted the company's ability to meet product demand[63]. - The company faces risks from increased competition in the RFID industry, which may lead to downward pressure on pricing and reduced margins[44]. - The company is vulnerable to supply disruptions due to reliance on suppliers and contract manufacturers[63]. - Adverse global economic conditions, including inflation and geopolitical tensions, may materially affect the company's financial condition[58]. Research and Development - The company employs 155 employees, with 24 in R&D, indicating a strong focus on innovation and product development[39]. - The company has a robust R&D team in Germany and Southeast Asia, focusing on advanced RFID and BLE technologies[33]. - Research and development expenses decreased by 16% to $3.3 million in 2025, representing 15% of net revenue, due to realignment of personnel and transition of activities to Thailand[146][147]. Supply Chain and Manufacturing - The manufacturing facility in Thailand is certified to ISO 9001:2015 and ISO 14001:2015 standards, ensuring high-quality production[35]. - The company transitioned all RFID inlay, tag, and label production to a new manufacturing facility in Thailand, significantly reducing manufacturing overhead costs and increasing production efficiency[131]. - Approximately 15% of the company's business is exposed to U.S. tariffs due to manufacturing in Thailand, which may increase costs unless offset by other strategies[135]. Shareholder and Stock Information - As of March 2, 2026, 1,092,015 shares are reserved for future grants under equity incentive plans, and 8,756,341 shares are reserved for other potential issuances[96]. - The company has not repurchased any shares under the Stock Repurchase Program in 2025, following the repurchase of 463,779 shares for approximately $1.9 million in 2024[161]. - Stockholders' equity decreased from $154.069 million in 2024 to $140.701 million in 2025, reflecting the impact of net losses on equity[204]. Currency and Tax Considerations - The company’s financial results may be affected by changes in foreign currency exchange rates and compliance with foreign laws[78]. - A significant portion of the company's business is conducted in foreign currencies, primarily the Euro and Thai Baht, which may lead to currency exchange gains and losses[85]. - The company has federal and state income tax net operating loss carryforwards of $96.5 million and $46.5 million, respectively, which will expire at various dates[182]. Legal and Compliance Risks - The company faces risks from third-party claims and litigation, which could adversely affect its results of operations and incur substantial costs[89]. - The likelihood of intellectual property infringement claims may increase as the number of products and competitors in the RFID market grows[90]. - The complexity of European patent laws has increased, with a new unitary patent system effective from June 1, 2023, impacting European patents[87].

Financial Performance - As of December 31, 2025, total revenue for DBM Global Inc. (DBMG) was $1,210.3 million, with SSC contributing $687.5 million (56.8%), Banker Steel $246.3 million (20.3%), and GrayWolf $237.4 million (19.6%) [33] - DBMG's sales pipeline includes approximately $10.6 billion in potential revenue generation, indicating strong future growth prospects [34] - DBMG operates with a total backlog of $1,723.9 million as of December 31, 2025, with 39.5% of this backlog having minimal bonding requirements [37] - The company experiences seasonal fluctuations, with the highest revenues typically in the fiscal fourth quarter and lowest in the first fiscal quarter [62] Customer Base and Market Strategy - DBMG's two largest customers represented approximately 22.1% of its revenues in 2025, down from 25.5% in 2024, suggesting a diversification in customer base [33] - The company aims to expand and diversify its revenue base by targeting projects with higher margins and less risk of large margin fluctuations [36] - DBMG's strategic focus includes pursuing large, value-added projects, leveraging its full range of steel construction services to achieve higher margins [31] Workforce and Operations - The company has 3,587 full-time employees and 151 part-time employees, indicating a stable workforce to support its operations [24] - DBMG's workforce consisted of 3,525 full-time and 141 part-time employees as of December 31, 2025 [3] - Approximately 23.9% of DBMG's employees are covered under various collective bargaining agreements [3] Cost Management and Supply Chain - DBMG has secured fixed price agreements from steel mills to limit raw material cost exposure, enhancing its cost management strategy [37] - DBMG purchased approximately 67.2% of the total value of steel and steel components from two domestic steel vendors in 2025 [2] Innovation and Technology - The company emphasizes innovative services, particularly in building information modeling (BIM) and digital engineering, to maintain a competitive edge in complex projects [36] - R2 Technologies has developed CryoAesthetics™ technologies for skin lightening and brightening, addressing a fast-growing segment in aesthetic dermatology [4] - R2 Technologies has a patent portfolio comprising 129 issued patents and 7 pending applications as of December 31, 2025 [75] - The Glacial Rx product is FDA cleared and is used for various dermatologic procedures, enhancing patient experience and generating additional revenue [68] - The Glacial fx product was launched in Q3 2023, expanding R2's North America market into non-medical and retail chains [67] Competition and Market Challenges - R2 Technologies faces significant competition in both U.S. and international markets, with many aesthetic products available internationally due to less stringent regulations [63][64] - The company is adapting to changes in federal legislation and FCC rules that may affect its operations and financial results [108] - Broadcasting's strategy focuses on attracting high-quality content providers for nationwide distribution, leveraging its national footprint and cloud infrastructure [107] - The company faces increasing competition from streaming services, digital platforms, and Full Power stations, which impacts its market share [103] Partnerships and Investments - MediBeacon, a partner company, received FDA approval for its TGFR system in January 2025, which assesses kidney function without requiring blood draws [80] - MediBeacon's partnership with Huadong includes a $30 million investment for exclusive commercialization rights in Greater China, with approximately $31.4 million received by December 31, 2025 [84] - Following FDA approval in January 2025, Pansend's convertible notes totaling $12.9 million were converted into Series 3 Preferred Stock [86] - Huadong's investment in MediBeacon's preferred stock was received at a pre-money valuation of approximately $420 million [86] Broadcasting Operations - HC2 Broadcasting operated 257 stations as of December 31, 2025, including three Full Power stations and 201 Low Power Television (LPTV) stations [92] - Broadcasting's stations can broadcast approximately 2,000 subchannels and reach 112 markets in the U.S. and Puerto Rico, including 39 of the top 40 markets [92] - Broadcasting operates 252 stations connected to a cloud-based IP backbone, allowing for remote operation and significant cost savings [107] - The company generates revenue primarily from the sale of television airtime, with contracts typically being short-term in nature [102] Regulatory and Compliance - DBMG's operations are affected by various federal, state, and local environmental protection laws, which have become increasingly stringent [6] - Broadcasting's FCC licenses must be renewed every eight years, with the next renewal cycle expected in 2025 [105] - Environmental regulations have not materially impacted the company's capital expenditures or competitive position [112] Company Information - INNOVATE was incorporated in 1994 and is based in Delaware [113] - The company provides free access to its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K on its website [113] - Details regarding executive officers, directors, and code of conduct are included in Item 10 of the Form 10-K [114] - Information about the Audit Committee and Financial Expert will be available in the 2026 Proxy Statement [114] - There are no applicable quantitative and qualitative disclosures about market risk [468]